Drug major Lupin has received approval from the US health regulator to market a generic version of Novartis' inhalation product Tobi, which is used to treat cystic fibrosis, in the American market.
The company has received final approval from the US Food and Drug Administration (USFDA) for its Tobramycin Inhalation Solution, the Mumbai-based company said in a statement.
The drug is indicated for management of cystic fibrosis patients.
As per IMS MAT December 2016 sales data, Tobramycin inhalation solution had sales of USD 133.6 million in the US market.
The stock today closed 1.58 per cent higher at Rs 1,490 on BSE.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)